Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Short Interest Down 16.0% in December

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) was the target of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 3,620,000 shares, a drop of 16.0% from the December 15th total of 4,310,000 shares. Based on an average trading volume of 3,270,000 shares, the short-interest ratio is currently 1.1 days.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Point72 DIFC Ltd acquired a new stake in Marinus Pharmaceuticals during the 2nd quarter valued at $28,000. AQR Capital Management LLC raised its position in shares of Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth about $64,000. World Investment Advisors LLC bought a new stake in shares of Marinus Pharmaceuticals during the 3rd quarter worth about $104,000. Finally, JPMorgan Chase & Co. grew its stake in Marinus Pharmaceuticals by 1,968.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock valued at $234,000 after buying an additional 126,752 shares during the last quarter. 98.80% of the stock is currently owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Price Performance

MRNS stock traded down $0.00 during trading hours on Friday, reaching $0.54. The stock had a trading volume of 1,393,785 shares, compared to its average volume of 2,936,145. The stock has a 50-day simple moving average of $0.37 and a 200 day simple moving average of $0.99. Marinus Pharmaceuticals has a fifty-two week low of $0.22 and a fifty-two week high of $10.50. The stock has a market capitalization of $29.81 million, a PE ratio of -0.22 and a beta of 1.03.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Jefferies Financial Group reaffirmed a “hold” rating and set a $0.50 price objective (down from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Truist Financial downgraded Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. EF Hutton Acquisition Co. I upgraded shares of Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Cantor Fitzgerald restated an “overweight” rating and set a $4.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $2.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.